Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E43.66 EPS (ttm)9.96 Insider Own0.40% Shs Outstand107.33M Perf Week0.83%
Market Cap46.69B Forward P/E26.14 EPS next Y16.64 Insider Trans-24.18% Shs Float79.18M Perf Month-8.96%
Income1.15B PEG2.41 EPS next Q3.83 Inst Own71.70% Short Float2.65% Perf Quarter-13.37%
Sales5.24B P/S8.92 EPS this Y39.50% Inst Trans1.40% Short Ratio2.73 Perf Half Y13.70%
Book/sh52.07 P/B8.35 EPS next Y11.73% ROA15.50% Target Price495.78 Perf Year7.63%
Cash/sh11.81 P/C36.82 EPS next 5Y18.09% ROE23.90% 52W Range325.35 - 543.55 Perf YTD18.49%
Dividend- P/FCF47.64 EPS past 5Y38.80% ROI18.20% 52W High-19.98% Beta1.65
Dividend %- Quick Ratio3.40 Sales past 5Y61.30% Gross Margin94.20% 52W Low33.69% ATR11.43
Employees5400 Current Ratio3.80 Sales Q/Q21.20% Oper. Margin32.30% RSI (14)34.91 Volatility2.12% 2.48%
OptionableYes Debt/Eq0.13 EPS Q/Q97.80% Profit Margin22.10% Rel Volume0.59 Prev Close438.15
ShortableYes LT Debt/Eq0.13 EarningsNov 02 BMO Payout0.00% Avg Volume769.29K Price434.97
Recom2.30 SMA20-5.39% SMA50-8.45% SMA2002.60% Volume453,374 Change-0.73%
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Sep-26-17 10:24AM  Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal Zacks
Sep-25-17 10:49AM  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer Zacks
Sep-22-17 11:17AM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : September 22, 2017 Capital Cube
10:41AM  The Medicines Co. Continues to Focus on Pipeline Development Zacks
09:53AM  Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions Zacks
Sep-21-17 11:01AM  Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up Zacks
10:15AM  How is the Age-Related Macular Degeneration Space Faring Now? Zacks
Sep-20-17 02:10PM  ProQR's Genetic Disorder Candidate Gets Orphan Drug Status Zacks
11:22AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
10:36AM  Teva/Nuvelution to Speed Up Development of Austedo in US Zacks
08:08AM  What Analysts Recommend for Zoetis and Peers in September 2017 Market Realist
Sep-19-17 02:59PM  [$$] Regeneron's Biggest Long-Term Opportunity
10:37AM  Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks
10:35AM  Pluristem's Ischemia Candidate Gets Fast Track Designation Zacks
09:19AM featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group Zacks
Sep-18-17 10:23AM  Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU Zacks
09:07AM  Regeneron Is Focused on Advancing Development of Fasinumab for Chronic Pain Market Realist
07:37AM  Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017 Market Realist
Sep-16-17 02:17AM  Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis GlobeNewswire
02:15AM  Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-15-17 10:38AM  Label Expansion in Asthma Indication May Boost Dupixents Sales Market Realist
09:10AM  Regulatory Approval in Asthma Indication May Boost Dupixents Sales Market Realist
07:38AM  Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis Market Realist
Sep-14-17 11:25AM  Glaxo's Shingles Candidate Gets Positive FDA Committee Vote Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
10:39AM  Eylea Leads the Retinal Diseases Sector Market Realist
09:36AM  Regeneron Is Focused on Increasing Awareness for Eylea in 2017 Market Realist
08:09AM  Analysts Recommendations for Regeneron in September 2017 Market Realist
Sep-13-17 06:02PM  Alexion to Restructure Operations, to Lower Headcount by 20% Zacks
08:33AM  Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data Zacks
07:16AM  Regeneron's Dupixent Takes Another Step Toward Blockbuster Status Motley Fool
Sep-12-17 01:26PM  Sanofi indicates dupilumab could be used to treat nasal polyps Reuters
11:25AM  AstraZeneca's Asthma Candidate Shows Promising Results Zacks
08:53AM  Regeneron's Delivery Isn't Matching the Hype Bloomberg
06:48AM  5 Things Regeneron's CEO Said as the Biotech Stock Sank Motley Fool
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market -5.60%
04:30PM  Federated, Carnival, Alphabet climb; Regeneron skids Associated Press
04:30PM  Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today Motley Fool
04:22PM  Here's Why Regeneron Toppled Despite A Successful Drug Trial Investor's Business Daily
03:30PM  Regeneron: When Good Isn't Good Enough
03:17PM  AstraZeneca's Lung Cancer Study Data Promising, Shares Spike Zacks
02:15PM  Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints Zacks
01:08PM  Regeneron, Sanofi asthma drug data fails to excite investors Reuters
10:58AM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
09:33AM  5 Top-Ranked Biotech Stocks to Buy Right Now Zacks
07:25AM  Featured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA ACCESSWIRE
01:14AM  Sanofi and Regeneron announce positive dupilumab topline results Reuters
01:00AM  Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma PR Newswire
Sep-08-17 05:42PM  Regeneron's Cemiplimab Gains Breakthrough Therapy Status Zacks
04:50PM  The Hot Stock: AbbVie Jumps 6.1%
04:32PM  Why The Biotech 'Catch-Up Rally' Could Add Another 15%-20% Investor's Business Daily
01:17PM  Feds want to deny Martin Shkreli bail Yahoo Finance Video
09:54AM  Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth Zacks
02:59AM  Sanofi says Cemiplimab skin cancer treatment gets FDA "Breakthrough Designation" Reuters
01:00AM  Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Sep-07-17 07:30PM  AbbVie Scores 2 Wins: 1 Threatens Regeneron Motley Fool -5.66%
10:52AM  Why Regeneron Is Getting Smoked
10:18AM  AstraZeneca's COPD Candidate Duaklir Reports Positive Data Zacks
Sep-06-17 06:14PM  ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA Zacks
06:09PM  VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug Zacks
02:00PM  Regeneron Pharmaceuticals Ready to Make All-Time Highs
08:57AM  Why Regeneron (REGN) Could Be Positioned for a Surge Zacks
Sep-05-17 02:26PM  4 Biotech Stocks to Improve Your Portfolio's Health Zacks
09:56AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences Zacks
Sep-04-17 04:42PM  Here Are 3 Strong Biotech Stocks In 2017 Forbes
09:51AM  Why Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report? Zacks
Sep-01-17 05:13PM  AMAG's Filing for Feraheme's Label Expansion Accepted by FDA Zacks
10:16AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : September 1, 2017 Capital Cube
07:35AM  5 Winning Stocks to Beat September Blues Zacks
Aug-31-17 04:01PM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
11:15AM  Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia Zacks
10:36AM  Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion Zacks
Aug-30-17 11:10AM  BioMarin's Pegvaliase BLA Granted Priority Review by the FDA Zacks
07:37AM  Dupixent and Kevzara: Regenerons Long-Term Growth Drivers? Market Realist
Aug-29-17 05:46PM  Advanced Accelerator Gets Action Date for Lutathera from FDA Zacks
05:21PM  Novo Nordisk's Tresiba Gets Canadian Nod Zacks
05:06PM  How Did Regenerons Eylea and Praluent Perform in 2Q17? Market Realist
03:37PM  Regeneron Pharmaceuticals Witnessed Solid Growth in 2Q17 Market Realist
01:59PM  Analyst Recommendations for Regeneron Pharmaceuticals in August Market Realist
11:04AM  September Could be Kind to Biotechnology ETFs ETF Trends
10:30AM  The Zacks Analyst Blog Highlights: Toyota Motor, NVIDIA and Regeneron Zacks
08:03AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-28-17 12:34PM  Kamada (KMDA) Gets FDA Approval for Rabies Vaccine Zacks
08:04AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
06:56AM  AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting Zacks
Aug-27-17 01:18PM  Novartis hopeful for novel heart drug, despite 'modest' benefit Reuters
05:00AM  Novartis hopeful for novel heart drug, despite 'modest' benefit Reuters
Aug-25-17 06:06PM  Will Endo (ENDP) Continue to Disappoint Investors in 2017? Zacks
12:08PM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax, Inc. Motley Fool
08:00AM  Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 PR Newswire
Aug-22-17 03:20PM  What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline? Motley Fool
03:17PM  What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here? Motley Fool
03:04PM  Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug Motley Fool
11:02AM  Alkermes Initiates Rolling Submission of Depression Drug Zacks
10:56AM  Inside Incytes Valuation after the 2Q17 Earnings Market Realist
10:10AM  4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings Zacks
10:04AM  Alexion's (ALXN) Soliris' Label Expansion Approved in Europe Zacks
08:41AM  Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough Zacks
08:05AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Aug-21-17 08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM